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A B S T R A C T
Background: Luteinized thecoma with sclerosing peritonitis (LTSP) is a very rare condition, and its clinical
management is not evidence-based. Here we describe a case of long-term disease control achieved with leu-
prorelin and tamoxifen therapy.
Case presentation: A 18-year-old woman with acute abdomen underwent surgical removal of an ovarian mass
and received diagnosis of LTSP. Treatment plan consisted of leuprorelin and tamoxifen, followed by a good
instrumental response. After 5 years, leuprorelin was stopped, and the patient continued tamoxifen alone. Ten
years after diagnosis, she is still disease free.
Conclusion: Even in the absence of solid evidence, the combination of leuprorelin and tamoxifen could be
considered as a possible medical treatment of LTSP. Considering the limitations related to the rarity of disease,
further studies are needed to improve its management.
1. Introduction
Thecoma is a very uncommon cancer, originated by ovarian theca
cells, that represents less of 5% of all ovarian cancers (Chechia et al.,
2008). It arises normally in young and midlife women, presenting as a
single round mass in the abdomen. An even rarer variant of thecoma is
luteinized thecoma with sclerosing peritonitis (LTSP). This entity was
originally described in 1994 and represents less than 0.01% of all
ovarian cancers (Clement et al., 1994). Sclerosing peritonitis, that is a
complication of this kind of cancer, consists of an abnormal prolifera-
tion of fibroblasts below the mesothelium, resulting in the growth of a
mass of fibrous tissue that incorporates abdominal organs (Iwasa et al.,
1996). The consequence is the progressive incarceration of intestinal
loops, followed by clinically relevant gut obstruction. Nowadays, the
pathogenesis of LTSP is still unknown; an association between this
condition and antiepileptic drugs administration was proposed based
on clinical observations (Levavi et al., 2009). Currently, there are no
clear guidelines about the management of LTSP, and the few available
evidences are mostly based on the description of single cases. Surgery is
burdened by a high mortality rate; therefore, it is normally reserved to
the emergency treatment of intestinal obstruction. Regarding the
pharmacological therapy, a single case of objective response to hor-
monal therapy has been reported in literature: after surgical resection of
thecoma, a 39-year-old patient was treated with toremifene and leu-
prorelin, achieving the complete regression of peritoneal lesions after
3months of therapy (Bianco et al., 2005). Another case report showed a
similar therapeutic result with the combination of corticosteroid and
leuprorelin in a 25-year-old patient with LTSP (Schonman et al., 2008).
Here we report the very long follow-up (10 years) of an 18-year-old
woman affected by LTSP, treated with leuprorelin and tamoxifen.
2. Case presentation
An 18-year-old woman was admitted to the emergency room in
February 2008 because of the progressive onset of severe abdominal
pain. An exploratory laparotomy was performed, showing appendicitis,
and a right ovarian mass. The patient underwent appendicectomy and
left salpingo-oophorectomy, and a biopsy of the ovarian mass was
performed, without removing the mass. The histological exam showed
only cells of ovarian fibroma with hemorrhagic infarction. One month
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later, due to the occurrence of a partial bowel obstruction, the patient
was again referred to the surgeons. Another laparotomy was performed
and the ovarian mass in the right ovary was completely removed, as
well as a portion of peritoneum. The histological examination showed
cells of luteinized thecoma (Fig. 1), associated with follicular cysts and
granulosa-cells hyperplasia, and sclerosing peritonitis with foreign-
body giant cells (Fig. 2). Expression of estrogen-receptors (Fig. 3) and
progesterone-receptors (Fig. 4) was detected by immunohistochemistry
on thecoma cells. No assumption of antiepileptic drugs was reported by
the patient. The case was initially assessed by gynecologist and hor-
monal therapy with the aromatase inhibitor letrozole, 2.5mg/day was
suggested. Because of the extreme rarity of the disease, the patient was
collectively evaluated by a multidisciplinary team of gynecologists and
oncologists, in June 2008. A treatment with leuprorelin 3.75mg/month
and tamoxifen 20mg/day was started and the hormonal therapy with
letrozole was suspended. In the next two months, the patient experi-
enced a relevant clinical improvement, moving to a regular function of
bowel and she regularly restarted oral intake of food. A single episode
of severe vomiting occurred in May 2008, and the patient underwent a
CT scan that showed a thickening of intestinal loops, compatible with
sclerosing peritonitis, and a mild amount of peritoneal effusion. How-
ever, this episode resolved spontaneously, and the patient continued
the hormonal treatment with leuprorelin and tamoxifen. In December
2009, after 18 months of disease stabilization and progressive resorp-
tion of peritoneal effusion, as showed in two follow-up CT scans, the
patient had a new episode of partial bowel obstruction. At that time, an
MRI of abdomen was conducted, showing that the sclerosing peritonitis
was substantially unchanged. During next four years, the patient did
not develop any other episode of complete or partial bowel obstruction,
but a bone densitometry showed a condition of osteoporosis (T-score of
femoral neck: −2.1), and a therapy with zoledronic acid (a single in-
travenous infusion of 5mg, administered once a year) was initiated.
Because of the complete absence of symptoms, no radiological re-as-
sessments were conducted until October 2013, when a new CT scan
showed the complete regression of peritoneal lesions. Based on this
favorable CT findings, and considering the time elapsed from diagnosis,
after multidisciplinary re-assessment, therapy with leuprorelin was
stopped, while continuing tamoxifen. In February 2014, after five years,
also the treatment with zoledronic acid was suspended. In April 2014,
the patient underwent a further CT scan, that confirmed the absence of
the relapse of the disease. Nowadays, the patient is continuing her
follow-up, and since the last CT scan, she did not show any sign or
symptom related to the relapse of the disease. In April 2018, within
multidisciplinary re-assessment, considering the time of ten years
elapsed from starting of hormonal treatment with leuprorelin and ta-
moxifen, the decision to stop tamoxifen was taken.
Fig. 1. Cells of thecoma, immunohistochemistry positive for inhibin (40×).
Fig. 2. Sclerosing peritonitis with granulomas and foreign-body giant cells
(20×).
Fig. 3. Immunohistochemical expression of estrogen-receptors (40×).
Fig. 4. Immunohistochemical expression of progesterone-receptors (40×).
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3. Discussion
To our knowledge, this case represents the first experience of a long-
term disease control in a patient with LTSP treated with leuprorelin for
5 years and tamoxifen for 10 years. LTSP is a very uncommon disease,
with a few cases reported in literature and scanty evidence about ef-
fective treatments. The first attempts of a systemic treatment for this
disease were based on the hypothesis that hormonal stimulation could
drive the growth of this neoplasm, even triggering the formation of
fibrous tissue in the peritoneum. At the same time, tamoxifen had al-
ready shown activity in the treatment of fibrosis associated with peri-
toneal dialysis, a clinical-radiological condition similar to thecoma-re-
lated sclerosing peritonitis (Bajo et al., 2003). In the present case, a
hormonal therapeutic approach with an aromatase inhibitor, not jus-
tified by the existing evidence, was initially attempted, but shortly in-
terrupted thereafter in favor of a treatment with leuprorelin plus ta-
moxifen, based on the already mentioned case report that, at the time of
diagnosis, represented the only treatment experience that had demon-
strated activity (Bianco et al., 2005). However, the management of the
disease was not without complications. First of all, the clinical history
was characterized, mainly in the first years, by repeated episodes of
partial bowel obstruction caused by the develop of abdominal adhe-
sions, which was followed by a progressive impairment of food oral
intake and weight loss, as well as therapy discontinuation. Secondly,
the effect of bone depletion induced by leuprorelin prevailed over the
bone protective effect of tamoxifen, causing osteoporosis that required
bisphosphonate therapy. However, hormonal therapy has been suc-
cessful and the patient now, disease-free ten years after diagnosis, could
be considered potentially healed. Nowadays, despite the time elapsed,
the evidence about the treatment of this disease is substantially un-
changed. In 2008, a review of 27 cases of LTSP was published, in which
the immunohistochemical profile of the primary ovarian lesion was
evaluated, reporting that a subgroup of patients had tumor cells ex-
pressing estrogen (ER) and progesterone (PgR) receptors (Staats et al.,
2008). This receptor status would justify the successes obtained with
hormonal therapy, but at the same time it suggests that patients ben-
efiting from this approach could represent only a subgroup of the
overall group of patients with a diagnosis of thecoma. In the future,
patients with thecoma should be investigated for the
immunohistochemical positivity of ER and PgR receptors, which could
help to select the patients who would most likely benefit from hormonal
treatment. However, the rarity of the disease makes hard to adequately
describe the interaction between the efficacy of treatments and poten-
tial predictive factors. Generally, the rarity of the disease makes un-
realistic any attempt to perform randomized clinical trials and produce
solid evidence-based treatment guidelines. Therefore, reporting the
clinical experience of individual cases or collecting retrospective series
represent a potentially useful way to accumulate novel data, that over
time could potentially improve the management of this rare disease.
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